Top Markets
#1 Akedo Akedo +54.06%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +50.26%
#4 Cross Cross +47.18%
#5 Black Phoenix Black Phoenix +34.15%
#6 Velvet Velvet +31.77%
#7 OVERTAKE OVERTAKE +18.70%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.05%
#9 Movement Movement +13.43%
#10 Perle Perle +11.98%
Coin of the day
Akedo Akedo
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
RepliCel Life Sciences Inc. RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc.

RP
Rang in Aktien #38777
Headquartered in Vancouver, Canada, RepliCel Life Sciences Inc. is a... Headquartered in Vancouver, Canada, RepliCel Life Sciences Inc. is a regenerative medicine company dedicated to developing innovative autologous cell therapies. These treatments are designed to correct functional cellular deficiencies by harnessing a patient's own cells. The process involves isolating cells from harvested tissues, significantly expanding them in a controlled laboratory environment, and subsequently applying them therapeutically. The company's developmental portfolio includes several key product candidates: RCT-01 targets chronic tendinosis, RCS-01 addresses aging and sun-damaged skin, and RCH-01 is aimed at treating hair loss. Additionally, RepliCel is advancing RCI-02, a specialized dermal injection device. RepliCel has established significant strategic alliances. It holds a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. to establish a clinical research program and facilitate the commercialization of RCS-01 and RCT-01. A similar collaboration exists with Shiseido Company, Limited, focusing on the clinical research program for RCH-01. Furthermore, the company is engaged in a research project agreement with the University of British Columbia, contributing to the creation of a comprehensive hair follicle cell data map.
Aktienkurs
$0.01100905
Zuletzt synchronisiert: 2025-02-28
Marktkapitalisierung
$810.02K
Veränderung (1 Tag)
58.98%
Veränderung (1 Jahr)
0.00%
Land
CA
Handel RepliCel Life Sciences Inc. (RP)

Kategorie

Healthcare
Operative Marge für RepliCel Life Sciences Inc. (RP)
Operative Marge zum 2026 TTM: 0.00%
Laut den neuesten Finanzberichten und dem Aktienkurs von RepliCel Life Sciences Inc. beträgt die aktuelle operative Marge (TTM) 0.00%. Am Ende des Jahres 2026 lag die operative Marge bei 0.00%.
Historie der operativen Marge von RepliCel Life Sciences Inc. von 2026 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
Nicht genügend Daten für die angegebenen Daten.
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.97% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.